16018-82-9

Basic information

• Product Name: N-(4-FLUOROPHENYL)IMIDODICARBONIMIDIC DIAMIDE HYDROCHLORIDE
• Synonyms: N-(4-fluorophenyl)imidodicarbonimidic diamide
• CAS NO: 16018-82-9
• Molecular Formula: C₈H₁₀FN₅
• Molecular Weight: 195.2
• Mol File: 16018-82-9.mol

Chemical Properties

• Boiling Point: 396.3°Cat760mmHg
• Flash Point: 193.5°C
• Appearance: /
• Density: 1.44g/cm³
• Vapor Pressure: 1.72E-06mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: N-(4-FLUOROPHENYL)IMIDODICARBONIMIDIC DIAMIDE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-FLUOROPHENYL)IMIDODICARBONIMIDIC DIAMIDE HYDROCHLORIDE(16018-82-9)
• EPA Substance Registry System: N-(4-FLUOROPHENYL)IMIDODICARBONIMIDIC DIAMIDE HYDROCHLORIDE(16018-82-9)

Safety Data

• Hazardous Substances Data: 16018-82-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H10FN5/c9-5-1-3-6(4-2-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)

Upstream product

• 127099-85-8 N-Cyanoguanidine 
• 371-40-4 4-fluoroaniline 
• 16018-83-0 1-carbamimidamido-N-(4-fluorophenyl)methanimidamide hydrochloride 

Relevant articles and documents

NOVEL CYCLIC GMP-AMP SYNTHASE (CGAS) INHIBITORS AND THEIR METHOD OF USE

Methods of treating diseases related to cGAS activation. Small molecule inhibitors of cGAS and pharmaceutical compositions and uses thereof in treating autoimmune diseases or inflammation.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-α, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

Synthesis and in Vitro AMPK Activation of Cycloalkyl/Alkarylbiguanides with Robust in Vivo Antihyperglycemic Action

This work describes the design, synthesis in one step, and the in vitro, in vivo, and in silico antidiabetic evaluation of a series of ten alicyclic and aromatic (alkyl +aryl: alkaryl)biguanides, analogues of metformin and phenformin. The design was conceived using isosteric replacement, chain-ring transformation, and lower and higher homologation strategies. All compounds were obtained as crystals and their structure was confirmed on the basis of their spectral data (NMR and mass spectra), and their purity was ascertained by microanalysis. Compounds were in vitro evaluated as activators of AMP-Activated Protein Kinase (AMPK). The results indicated that compounds 4, 5, and 6 showed similar or even better effect compared to metformin. Docking analysis was performed with regulatory subunit γ of AMPK, showing several interactions with nucleotide binding pocket. The in vivo evaluation of compounds 4-6 at a single dose of 50 mg/kg was performed in a murine experimental model of diabetes. The results showed an important and robust decrease of plasmatic glucose levels (-40%). Compound 6 was selected for an oral glucose tolerance test, showing an antihyperglycemic effect similar to metformin. The in vivo results indicated that compounds 4-6 may be effective in treating experimental T2DM.

Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents

The discovery of a novel class of HCV inhibitors is described. The new amidinourea compounds were designed as isosteric analogues of the antiviral drug moroxydine. The two derivatives 11g and 11h showed excellent HCV inhibition activity and viability and proved to inhibit a step(s) of the RNA replication. The new compounds have been synthesized in only three synthetic steps from cheap building blocks and in high yields, thus turning to be promising drug candidates in the development of cheaper HCV treatments.